US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

California Resources

34.63

+0.21000.61%

Post-market: 36.261.63+4.71%17:54 EDT

Volume:476.46K

Turnover:16.58M

Market Cap:3.14B

PE:7.50

High:35.39

Open:34.37

Low:34.37

Close:34.42

Loading ...

Overview Company News Filings

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

California Resources Price Target Maintained With a $68.00/Share by RBC Capital

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

California Resources Corp (CRC) Receives a Rating Update from a Top Analyst

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries

UBS Cuts Price Target on California Resources to $61 From $65, Keeps Buy Rating

MT Newswires Live

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

California Resources Faces Permit Challenges And Oversupply Risks—Analyst Sees Growth, But Stay Cautious

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

CMS approves Guardant Health ADLT status for Shield CRC screening test

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

California Resources Corporation (NYSE:CRC) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Simply Wall St.

Director’s Bold Move: Major Stock Purchase at California Resources Corp!

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRC\",,,,,undefined,":{"symbol":"CRC","market":"US","secType":"STK","nameCN":"California Resources","latestPrice":34.63,"timestamp":1744833600000,"preClose":34.42,"halted":0,"volume":476460,"hourTrading":{"tag":"盘后","latestPrice":36.26,"preClose":34.63,"latestTime":"17:54 EDT","volume":27521,"amount":953055.5325199999,"timestamp":1744840463288},"delay":0,"floatShares":89794414,"shares":90646665,"eps":4.62,"marketStatus":"Post-Mkt","change":0.21,"latestTime":"04-16 19:25:57 EDT","open":34.37,"high":35.39,"low":34.37,"amount":16577415.604799999,"amplitude":0.029634,"askPrice":47.5,"askSize":230,"bidPrice":33.02,"bidSize":7,"shortable":3,"etf":0,"ttmEps":4.62,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1744848000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1415854800000,"exchange":"NYSE","adjPreClose":34.42,"dividendRate":0.040283,"preHourTrading":{"tag":"盘前","latestPrice":34.01,"preClose":34.42,"latestTime":"04:32 EDT","volume":3,"amount":103.48999799999999,"timestamp":1744792333471},"postHourTrading":{"tag":"盘后","latestPrice":36.26,"preClose":34.63,"latestTime":"17:54 EDT","volume":27521,"amount":953055.5325199999,"timestamp":1744840463288},"volumeRatio":0.530455,"impliedVol":0.8132,"impliedVolPercentile":0.988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRC\",,,,,undefined,":{"symbol":"CRC","floatShares":89794414,"roa":"7.63%","roe":"13.06%","lyrEps":4.741488,"volumeRatio":0.530455,"shares":90646665,"dividePrice":1.395,"high":35.39,"amplitude":0.029634,"preClose":34.42,"low":34.37,"week52Low":30.97,"pbRate":"0.89","psRate":"1.07","week52High":60.41,"institutionHeld":0,"latestPrice":34.63,"committee":-0.940928,"eps":4.62,"divideRate":0.040283,"volume":476460,"delay":0,"ttmEps":4.62,"open":34.37,"prevYearClose":51.89,"prevWeekClose":34.33,"prevMonthClose":43.97,"prevQuarterClose":43.97,"fiveDayClose":36.47,"twentyDayClose":44.82,"sixtyDayClose":54.42,"earningDate":1746460800000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","IE00B66KJ199.SGD","BK4139","CRC","CR","IE0031619046.USD","LU0053666078.USD","PD","BK4585","RCC","BK4231","IE00B19Z4B17.USD","CRS","BK4107","SD","LU0456854461.SGD","LU2065731478.USD","LU0266512127.USD","PR","SNSE","SITC","BK4588","L","MSS","BK4080","BK4213","BK4006","BK4023","BK4113","IE00B7SZL793.SGD","BK4161","LU1169590202.USD"],"gpt_icon":0},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456854461.SGD","LU0266512127.USD","LU2125154935.USD","LU1868836757.USD","EXEL","IE00BFTCPJ56.SGD","BK4559","LU1074936037.SGD","IE0009355771.USD","IE00BFXG1179.USD","LU0154236417.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU1670710661.SGD","LU0321505439.SGD","LU0096364046.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","LU0237698245.USD","LU1718418525.SGD","LU0321505868.SGD","LU2360032135.SGD","LU1323610961.USD","LU1093756168.USD","LU1868837300.USD","LU1585245621.USD","BK4588","LU1868836914.USD","IE00BSNM7G36.USD","LU0882574055.USD","LU0225284248.USD","DTC","BK4534","LU0456855351.SGD","CRC","LU1261432733.SGD","LU1989771016.USD","IE0002141913.USD","LU1032466523.USD","BAYRY","BMY","BK4139","LU0306806265.USD","LU1093756325.SGD","LU1670710588.SGD","RCC","IE00BKVL7J92.USD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2522519588","title":"California Resources Price Target Maintained With a $68.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522519588","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522519588?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:00","pubTimestamp":1743087600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 11:00 ET (15:00 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC"],"gpt_icon":0},{"id":"2522305361","title":"Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305361","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305361?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:01","pubTimestamp":1743080460,"startTime":"0","endTime":"0","summary":"2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report To","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3050616/0/en/Mainz-Biomed-Enrolls-First-Patient-in-Its-eAArly-DETECT-2-Clinical-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0456854461.SGD","LU0266512127.USD","BK4213","CRC","MYNZ"],"gpt_icon":0},{"id":"2522378635","title":"California Resources Corp (CRC) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2522378635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522378635?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:39","pubTimestamp":1743071945,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Scott Hanold maintained a Buy rating on California Resources Corp (CRC – Research Report) yesterday and set a price target of $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/california-resources-corp-crc-receives-a-rating-update-from-a-top-analyst-13?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/california-resources-corp-crc-receives-a-rating-update-from-a-top-analyst-13?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRC"],"gpt_icon":0},{"id":"2522935496","title":"Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935496","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935496?lang=en_us&edition=fundamental","pubTime":"2025-03-27 03:00","pubTimestamp":1743015600,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's upbeat performance can be attributed to its strong quarterly results, raised guidance and efforts to increase shareholders' returns.Last month, Exelixis announced a new share repurchase program of $500 million. Shares rallied following the announcement. Earlier, the company reported better-than-expected fourth-quarter results, which also drove the stock higher.Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.Exelixis’ lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor  for the treatment of renal cell carcinoma  in both the frontline immuno-oncology  +TKI market and the second-line monotherapy segment.Meanwhile, Exelixis collaborated with pharma giant Merck MRK to evaluate zanzalinti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-rises-13-3-190000591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989772840.SGD","SG9999014567.USD","SG9999014542.SGD","LU0289739699.SGD","LU1718418525.SGD","LU2133065610.SGD","LU0306806265.USD","LU1989771016.USD","LU2242646821.SGD","IE00BFXG1179.USD","CRC","LU1699723380.USD","LU0306807586.USD","IE00BFTCPJ56.SGD","LU1974910355.USD","BK4581","BK4588","LU1670710588.SGD","BK4550","LU1037948897.HKD","MRK","LU1670710661.SGD","BK4516","LU1929549753.HKD","LU1868836591.USD","BK4585","LU1934455194.USD","LU1037948541.HKD","BK4559","LU2023250504.SGD","LU1868837136.USD","LU1941712264.USD","LU1868836914.USD","LU1670711123.USD","SG9999015341.SGD","LU1323610961.USD","LU0266512127.USD","RCC","SG9999015358.SGD","BMY","LU1430594728.SGD","SGXZ57979304.SGD","LU1989772923.USD","IE00BJT1NW94.SGD","EXEL","LU1868837300.USD","LU1057294990.SGD","LU1934455277.USD","LU1093756325.SGD","LU0061475181.USD"],"gpt_icon":0},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXN33.USD","BK4213","BK4113","LENZ","BK4097","BK4141","BK4505","OS","BK4211","IE00BMPRXQ63.HKD","CRC","BK4139","ORR","ONC","PFS","BK4609","LU0456854461.SGD","IE00BMPRXR70.SGD","BK4588","BK4543","LPTX","LU0266512127.USD","MSS","BK4195","BK4585","LU0348723411.USD","BK4563"],"gpt_icon":1},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4213","IE00BMPRXQ63.HKD","CRC","BK4097","LU0456854461.SGD","PFS","BK4141","BK4195","LU0266512127.USD","LENZ","BK4505","LPTX","BK4588","IE00BMPRXN33.USD","BK4563","LU0348723411.USD","ORR","MSS","IE00BMPRXR70.SGD","BK4585","BK4609","OS","BK4113","BK4139","BK4543"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXN33.USD","BK4213","BK4113","LENZ","BK4097","BK4141","BK4505","OS","BK4211","IE00BMPRXQ63.HKD","CRC","BK4139","ORR","PFS","BK4609","LU0456854461.SGD","IE00BMPRXR70.SGD","BK4588","ARM","BK4543","LPTX","LU0266512127.USD","MSS","BK4195","BK4585","LU0348723411.USD","BK4563"],"gpt_icon":0},{"id":"2522703838","title":"Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries","url":"https://stock-news.laohu8.com/highlight/detail?id=2522703838","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522703838?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"US veterans and eligible family members now have access to blood test for colorectal cancer screening with no copay. Benefit will cover all eligible individuals ages 45-84, representing first coverage beyond Medicare population for Shield. Following Medicare coverage for Shield in August 2024, the VA network coverage is the first for individuals between the ages of 45 and 64. The U.S. Department of Veterans Affairs  Community Care Network  consists of community-based practitioners who provide veterans with healthcare services and covers approximately 9.1 million beneficiaries.1. \"We are proud of the lifesaving value that the Shield blood test can bring to U.S. veterans and their families,\" said AmirAli Talasaz, Guardant Health co-CEO. \"This coverage decision by the VA is the first for younger and non-Medicare beneficiaries and we are excited to broaden the impact of our screening test to help detect more colorectal cancer early, when it is most treatable.\". The U.S. Food and Drug Admin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-shield-blood-test-200500564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRC","CMS","BK4551","LU1894683348.USD","BK4196","LU0456854461.SGD","LU2637428348.USD","CCN","BK4535","BK4588","LU1894683264.USD","LU2500361329.USD","BK4213","LU2346227817.USD","BK4585","LU0266512127.USD","GH","BK4208"],"gpt_icon":0},{"id":"2521772136","title":"UBS Cuts Price Target on California Resources to $61 From $65, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2521772136","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521772136?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:21","pubTimestamp":1742822468,"startTime":"0","endTime":"0","summary":"California Resources (CRC) has an average rating of buy and mean price target of $66.87, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRC"],"gpt_icon":0},{"id":"2521747504","title":"Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747504?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses. SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index. Cash balance of $85.2 million provides runway into late 2026. SAN DIEGO and SUZHOU, China, March 24, 2025  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel anti-body-based therapies, today reported financial results for the full year 2024 and provided corporate updates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adagene-reports-full-2024-financial-120000486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4213","HCC","LU0456854461.SGD","MSS","ADAG","BK4139","LU0266512127.USD","CRC","BK4113"],"gpt_icon":0},{"id":"2520880146","title":"Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520880146","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520880146?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:05","pubTimestamp":1742241900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc.   today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc.  to Sanofi S.A.  and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.Cash and Cash Equivalents. As of December31, 2024, Inhibrx had cash and cash equivalents of $152.6 million. Subsequent to year-end, the Company entered into the Oxford Loan Agreement and received gross proceeds of $100.0 million. As of February 28, 2025, Inhibrx had cash and cash equivalents of $230.5 million.Research and development expenses were $","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inhibrx-reports-fourth-quarter-fiscal-200500270.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inhibrx-reports-fourth-quarter-fiscal-200500270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4195","LU0456854461.SGD","SOFR","LU0266512127.USD","INBX","BK4213","CRC","PFS","BK4139"],"gpt_icon":0},{"id":"2519338212","title":"California Resources Faces Permit Challenges And Oversupply Risks—Analyst Sees Growth, But Stay Cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=2519338212","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519338212?lang=en_us&edition=fundamental","pubTime":"2025-03-15 01:21","pubTimestamp":1741972863,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Alejandra Magana maintained a Neutral rating on California Resources Corporation  with a price forecast of $63.Earlier in March, California Resources reported fourth-quarter 2024 adjusted EPS of $0.91, missing the $0.97 estimate and revenue of $877 million, falling short of the $897.75 million expectation.The analyst notes that the company delivered a strong fourth quarter, with EBITDA beating estimates, solid operations, and continued momentum in CCS volume agreements.Magana writes that the company faces challenges maintaining output due to strict California regulations.While the Aera acquisition bolstered the business, concerns remain about its oil exposure amid potential oversupply in 2025, adds the analyst.The analyst says that the company's permit inventory rebuild is stalled as CalGEM revises well procedures, and a new bill may allow local governments to impose further restrictions.Magana says the company is also exploring clean power, aiming to connect Elk Hi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/california-resources-faces-permit-challenges-172103454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","CRC","PSCE","LU0266512127.USD","LU0456854461.SGD"],"gpt_icon":0},{"id":"2519835947","title":"Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835947","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835947?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:00","pubTimestamp":1741867200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, March  13, 2025  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042117/0/en/Adagene-to-Present-at-11th-Annual-Immuno-Oncology-360-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LU0266512127.USD","BK4113","MSS","SMMF","ADAG","CRC","BK4211","LU0456854461.SGD","BK4139"],"gpt_icon":0},{"id":"2518748626","title":"CMS approves Guardant Health ADLT status for Shield CRC screening test","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748626","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748626?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:36","pubTimestamp":1741692998,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT status for th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cms-approves-guardant-health-adlt-status-for-shield-crc-screening-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cms-approves-guardant-health-adlt-status-for-shield-crc-screening-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMS","CRC","GH","LU1894683348.USD","BK4213","BK4551","LU2346227817.USD","BK4535","LU0456854461.SGD","LU0266512127.USD","BK4588","LU2500361329.USD","LU2637428348.USD","BK4196","BK4208","BK4585","LU1894683264.USD"],"gpt_icon":0},{"id":"2518710392","title":"Guardant Health Receives ADLT Status From CMS for Shield Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2518710392","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518710392?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:00","pubTimestamp":1741690800,"startTime":"0","endTime":"0","summary":"Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing. The CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that cannot be obtained by any other method, and for FDA-approved tests. Obtaining ADLT status initiates a specific, market-based approach to pricing the test for Medicare patients. The Shield test will be reimbursed at the amount of $1,495 for Medicare patients during the initial nine-month ADLT period beginning April 1, 2025.During the initial ADLT period, Guardant Health will collect, assess and submit private-payer payment rate data for the test, the median of which will be used by CMS to determine the Medicare pricing, beginning January 1, 2026. This rate will be the payment amount for Shield from January 1, 2026, to December 31, 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-receives-adlt-status-110000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CRC","GH","LU2637428348.USD","LU1894683348.USD","BK4196","LU2346227817.USD","BK4208","LU0266512127.USD","LU0456854461.SGD","BK4213","BK4535","BK4551","LU1894683264.USD","LU2500361329.USD","CMS","BK4588"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1291159041.SGD","CRC","ALK","LU0225284248.USD","IE00B19Z4B17.USD","LU0114720955.EUR","LU0306806265.USD","LU2125154935.USD","LU1868836914.USD","TEN","EC","LU1868836591.USD","BMY","BK4132","HCC","BK4532","LU1670710588.SGD","LU0306807586.USD","BK4201","MYE","BK4157","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU0096364046.USD","LU1261432733.SGD","BK4124","OS","RCC","IE00BSNM7G36.USD","LU1430594728.SGD","LU0237698245.USD","LU1571399168.USD","CRT","BK4097","IE00B7SZL793.SGD","LU1868837300.USD","HSCT","LU2242646821.SGD","ORR","AEIS","BK4213","LU1670711040.USD","LU1868837136.USD","VOD","LU0868494617.USD","LU1032466523.USD","LU0321505868.SGD","BK4581"],"gpt_icon":0},{"id":"2517402486","title":"California Resources Corporation (NYSE:CRC) Looks Like A Good Stock, And It's Going Ex-Dividend Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2517402486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517402486?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:44","pubTimestamp":1741344250,"startTime":"0","endTime":"0","summary":"The company's next dividend payment will be US$0.3875 per share, on the back of last year when the company paid a total of US$1.55 to shareholders. Looking at the last 12 months of distributions, California Resources has a trailing yield of approximately 3.8% on its current stock price of US$40.97. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.Check out our latest analysis for California Resources. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. That's why it's good to see California Resources paying out a modest 29% of its earnings. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated eno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/california-resources-corporation-nyse-crc-104410509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0266512127.USD","LU0456854461.SGD","BK4213","CRC","NYSE"],"gpt_icon":0},{"id":"2517814453","title":"Director’s Bold Move: Major Stock Purchase at California Resources Corp!","url":"https://stock-news.laohu8.com/highlight/detail?id=2517814453","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517814453?lang=en_us&edition=fundamental","pubTime":"2025-03-07 10:17","pubTimestamp":1741313867,"startTime":"0","endTime":"0","summary":"New insider activity at California Resources Corp ( ($CRC) ) has taken place on March 7, 2025. Director James Chapman has made a significant invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/directors-bold-move-major-stock-purchase-at-california-resources-corp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/directors-bold-move-major-stock-purchase-at-california-resources-corp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0456854461.SGD","BK4213","LU0266512127.USD","CRC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRC\",params:#limit:5,,,undefined,":[{"date":"2025-05-06","symbol":"CRC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.88,"defaultRemindTime":1746561600000,"name":null,"time":"Post Market","dateTimestamp":1746504000000,"actualEps":null},{"date":"2025-03-10","symbol":"CRC","amount":0.3875,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"加州资源","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-21"},{"market":"US","date":"2025-03-03","symbol":"CRC","fiscalQuarterEnding":"2024/12","expectedEps":0.96,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":0.91},{"date":"2024-12-02","symbol":"CRC","amount":0.3875,"announcedDate":"2024-11-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-02","defaultRemindTime":1733149800000,"name":"加州资源","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-16","payableDate":"2024-12-02","currency":"USD","dateTimestamp":1733115600000,"payDate":"2024-12-16"},{"date":"2024-11-05","symbol":"CRC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/09","expectedEps":0.88,"defaultRemindTime":1730840400000,"name":null,"time":"Post Market","dateTimestamp":1730782800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRC\",market:\"US\",,,undefined,":[{"executeDate":"2021-11-30","recordDate":"2021-12-01","paymentDate":"2021-12-16","value":0.17,"currency":"USD"},{"executeDate":"2022-03-04","recordDate":"2022-03-07","paymentDate":"2022-03-16","value":0.17,"currency":"USD"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-16","value":0.17,"currency":"USD"},{"executeDate":"2022-08-31","recordDate":"2022-09-01","paymentDate":"2022-09-16","value":0.17,"currency":"USD"},{"executeDate":"2022-11-30","recordDate":"2022-12-01","paymentDate":"2022-12-16","value":0.2825,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2143,"buy":0.5714,"hold":0.2143,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRC","date":"2025-04-15","current":8.290795,"percent":0.835093,"low":-4.935889,"twenty":0.667358,"median":3.694493,"eighty":7.739841,"high":29.507578,"avg":4.967379,"sd":6.589599,"marketCap":3117338809},"quantilePoints":[{"date":"2020-04-17","current":-2.908649,"twenty":-4.250974,"median":-0.143922,"eighty":1.522745,"marketCap":81442170},{"date":"2020-04-24","current":-4.160249,"twenty":-4.25544,"median":-0.147269,"eighty":1.464642,"marketCap":116486982},{"date":"2020-05-01","current":-4.036852,"twenty":-4.268681,"median":-0.153039,"eighty":1.442601,"marketCap":113031860},{"date":"2020-05-08","current":-4.177878,"twenty":-4.295208,"median":-0.162581,"eighty":1.420716,"marketCap":116980571},{"date":"2020-05-15","current":-2.626598,"twenty":-4.295208,"median":-0.184022,"eighty":1.393263,"marketCap":73544747},{"date":"2020-05-22","current":-2.538457,"twenty":-4.295208,"median":-0.192857,"eighty":1.375418,"marketCap":71076803},{"date":"2020-05-29","current":-2.344547,"twenty":-4.295208,"median":-0.200937,"eighty":1.357573,"marketCap":65647325},{"date":"2020-06-05","current":-3.543263,"twenty":-4.295208,"median":-0.20336,"eighty":1.341366,"marketCap":99211370},{"date":"2020-06-12","current":-2.661854,"twenty":-4.306077,"median":-0.205204,"eighty":1.323009,"marketCap":74531925},{"date":"2020-06-19","current":-2.644226,"twenty":-4.306077,"median":-0.207188,"eighty":1.282312,"marketCap":74038336},{"date":"2020-06-26","current":-0.036027,"twenty":-4.306077,"median":-0.209371,"eighty":1.269657,"marketCap":63300220},{"date":"2020-07-02","current":-0.033776,"twenty":-4.306077,"median":-0.209371,"eighty":1.250505,"marketCap":59343956},{"date":"2020-07-10","current":-0.032931,"twenty":-4.306077,"median":-0.209371,"eighty":1.226048,"marketCap":57860357},{"date":"2020-07-17","current":-0.009314,"twenty":-4.306077,"median":-0.209371,"eighty":1.210738,"marketCap":16364095},{"date":"2020-07-24","current":-0.006596,"twenty":-4.306077,"median":-0.209371,"eighty":1.196704,"marketCap":11589380},{"date":"2020-07-31","current":-0.006023,"twenty":-4.306077,"median":-0.209371,"eighty":1.180119,"marketCap":10583005},{"date":"2020-08-07","current":-0.00497,"twenty":-4.306077,"median":-0.209371,"eighty":1.169315,"marketCap":10137925},{"date":"2020-08-14","current":-0.003103,"twenty":-4.306077,"median":-0.209371,"eighty":1.155878,"marketCap":6330022},{"date":"2020-08-21","current":-0.002424,"twenty":-4.306077,"median":-0.209371,"eighty":1.137946,"marketCap":4945329},{"date":"2020-08-28","current":-0.002373,"twenty":-4.306077,"median":-0.209371,"eighty":1.121432,"marketCap":4841477},{"date":"2020-09-04","current":-0.00223,"twenty":-4.306077,"median":-0.209371,"eighty":1.109119,"marketCap":4549703},{"date":"2020-09-11","current":-0.001964,"twenty":-4.306077,"median":-0.209371,"eighty":1.099511,"marketCap":4005717},{"date":"2020-09-18","current":-0.002351,"twenty":-4.306077,"median":-0.209371,"eighty":1.086985,"marketCap":4796969},{"date":"2020-09-25","current":-0.002109,"twenty":-4.306077,"median":-0.209371,"eighty":1.080606,"marketCap":4302436},{"date":"2020-10-02","current":-0.002082,"twenty":-4.306077,"median":-0.209371,"eighty":1.069124,"marketCap":4248038},{"date":"2020-10-09","current":-0.001697,"twenty":-4.306077,"median":-0.209371,"eighty":1.046159,"marketCap":3461730},{"date":"2020-10-16","current":-0.001909,"twenty":-4.306077,"median":-0.209371,"eighty":1.039052,"marketCap":3894447},{"date":"2020-10-23","current":-0.001178,"twenty":-4.306077,"median":-0.209371,"eighty":1.018479,"marketCap":2403430},{"date":"2020-10-30","current":-0.547167,"twenty":-4.306077,"median":-0.210775,"eighty":1.002051,"marketCap":1116220000},{"date":"2020-11-06","current":-0.439133,"twenty":-4.306077,"median":-0.215303,"eighty":0.973809,"marketCap":949844819},{"date":"2020-11-13","current":-0.536975,"twenty":-4.306077,"median":-0.216571,"eighty":0.938992,"marketCap":1161476910},{"date":"2020-11-20","current":-0.590904,"twenty":-4.306077,"median":-0.218019,"eighty":0.914188,"marketCap":1278124520},{"date":"2020-11-27","current":-0.842442,"twenty":-4.306077,"median":-0.219356,"eighty":0.899442,"marketCap":1822202298},{"date":"2020-12-04","current":-1.030421,"twenty":-4.306077,"median":-0.22033,"eighty":0.892607,"marketCap":2228800905},{"date":"2020-12-11","current":-0.770408,"twenty":-4.306077,"median":-0.222998,"eighty":0.883681,"marketCap":1666393200},{"date":"2020-12-18","current":-0.808158,"twenty":-4.306077,"median":-0.223643,"eighty":0.862133,"marketCap":1748046466},{"date":"2020-12-24","current":-0.821255,"twenty":-4.306077,"median":-0.22525,"eighty":0.849685,"marketCap":1776375151},{"date":"2020-12-31","current":-0.908697,"twenty":-4.306077,"median":-0.227441,"eighty":0.838203,"marketCap":1965510779},{"date":"2021-01-08","current":-0.94375,"twenty":-4.306077,"median":-0.228513,"eighty":0.834376,"marketCap":2041331670},{"date":"2021-01-15","current":-0.96147,"twenty":-4.306077,"median":-0.230901,"eighty":0.834376,"marketCap":2079658713},{"date":"2021-01-22","current":-0.952225,"twenty":-4.306077,"median":-0.23285,"eighty":0.834376,"marketCap":2059661995},{"date":"2021-01-29","current":-0.889436,"twenty":-4.306077,"median":-0.235524,"eighty":0.834376,"marketCap":1923850949},{"date":"2021-02-05","current":-0.92449,"twenty":-4.306077,"median":-0.237422,"eighty":0.834376,"marketCap":1999671840},{"date":"2021-02-12","current":-0.980345,"twenty":-4.306077,"median":-0.239101,"eighty":0.834376,"marketCap":2120485347},{"date":"2021-02-19","current":-1.001531,"twenty":-4.306077,"median":-0.243277,"eighty":0.834376,"marketCap":2166311160},{"date":"2021-02-26","current":-1.012317,"twenty":-4.306077,"median":-0.244974,"eighty":0.834376,"marketCap":2189640664},{"date":"2021-03-05","current":-1.020791,"twenty":-4.307042,"median":-0.24807,"eighty":0.835141,"marketCap":2207970990},{"date":"2021-03-12","current":1.210636,"twenty":-4.307042,"median":-0.250121,"eighty":0.838203,"marketCap":2137982475},{"date":"2021-03-19","current":1.13845,"twenty":-4.307042,"median":-0.250121,"eighty":0.850388,"marketCap":2010503395},{"date":"2021-03-26","current":1.14883,"twenty":-4.306077,"median":-0.249299,"eighty":0.866271,"marketCap":2028833721},{"date":"2021-04-01","current":1.127127,"twenty":-4.306077,"median":-0.249299,"eighty":0.885408,"marketCap":1990506677},{"date":"2021-04-09","current":1.144112,"twenty":-4.307042,"median":-0.250121,"eighty":0.907117,"marketCap":2020501755},{"date":"2021-04-16","current":1.139866,"twenty":-4.307042,"median":-0.250121,"eighty":0.939757,"marketCap":2013002985},{"date":"2021-04-23","current":1.059188,"twenty":-4.307042,"median":-0.250121,"eighty":0.96943,"marketCap":1870526367},{"date":"2021-04-30","current":1.118163,"twenty":-4.307042,"median":-0.250121,"eighty":0.983134,"marketCap":1974675942},{"date":"2021-05-07","current":1.176194,"twenty":-4.307042,"median":-0.248184,"eighty":1.018359,"marketCap":2077159123},{"date":"2021-05-14","current":0.57973,"twenty":-4.307042,"median":-0.2454,"eighty":1.03654,"marketCap":2010503395},{"date":"2021-05-21","current":0.708505,"twenty":-4.307042,"median":-0.243788,"eighty":1.03654,"marketCap":2457096773},{"date":"2021-05-28","current":0.696973,"twenty":-4.307042,"median":-0.239857,"eighty":1.03654,"marketCap":2417103336},{"date":"2021-06-04","current":0.737816,"twenty":-4.307042,"median":-0.238075,"eighty":1.03654,"marketCap":2558746758},{"date":"2021-06-11","current":0.799561,"twenty":-4.307042,"median":-0.236957,"eighty":1.03654,"marketCap":2772878284},{"date":"2021-06-18","current":0.782984,"twenty":-4.307042,"median":-0.233507,"eighty":1.03654,"marketCap":2715387719},{"date":"2021-06-25","current":0.79836,"twenty":-4.307042,"median":-0.231347,"eighty":1.03654,"marketCap":2768712301},{"date":"2021-07-02","current":0.722921,"twenty":-4.307042,"median":-0.228622,"eighty":1.03654,"marketCap":2507088569},{"date":"2021-07-09","current":0.704181,"twenty":-4.307042,"median":-0.227828,"eighty":1.03654,"marketCap":2442099234},{"date":"2021-07-16","current":0.634508,"twenty":-4.307042,"median":-0.225451,"eighty":1.03654,"marketCap":2200472220},{"date":"2021-07-23","current":0.634988,"twenty":-4.307042,"median":-0.223277,"eighty":1.03654,"marketCap":2202138613},{"date":"2021-07-30","current":0.675351,"twenty":-4.307042,"median":-0.223131,"eighty":1.03654,"marketCap":2342115642},{"date":"2021-08-06","current":0.682705,"twenty":-4.307042,"median":-0.223131,"eighty":1.03654,"marketCap":2476853574},{"date":"2021-08-13","current":0.671872,"twenty":-4.307042,"median":-0.221697,"eighty":1.03654,"marketCap":2437551434},{"date":"2021-08-20","current":0.645015,"twenty":-4.307042,"median":-0.218296,"eighty":1.03654,"marketCap":2340114881},{"date":"2021-08-27","current":0.755828,"twenty":-4.307042,"median":-0.218003,"eighty":1.03654,"marketCap":2742143014},{"date":"2021-09-03","current":0.829402,"twenty":-4.307042,"median":-0.218003,"eighty":1.03654,"marketCap":3009070044},{"date":"2021-09-10","current":0.887629,"twenty":-4.307042,"median":-0.217706,"eighty":1.03654,"marketCap":3220319043},{"date":"2021-09-17","current":0.970457,"twenty":-4.307042,"median":-0.21731,"eighty":1.03654,"marketCap":3520816651},{"date":"2021-09-24","current":0.931864,"twenty":-4.307042,"median":-0.216391,"eighty":1.03654,"marketCap":3380802779},{"date":"2021-10-01","current":0.946534,"twenty":-4.307042,"median":-0.215187,"eighty":1.03654,"marketCap":3434024426},{"date":"2021-10-08","current":0.910424,"twenty":-4.306077,"median":-0.210775,"eighty":1.036368,"marketCap":3303017295},{"date":"2021-10-15","current":0.958947,"twenty":-4.306077,"median":-0.20336,"eighty":1.036368,"marketCap":3479058127},{"date":"2021-10-22","current":0.983772,"twenty":-4.306077,"median":-0.188207,"eighty":1.036368,"marketCap":3569125530},{"date":"2021-10-29","current":1.041097,"twenty":-4.303903,"median":-0.163857,"eighty":1.037057,"marketCap":3777099351},{"date":"2021-11-05","current":1.033875,"twenty":-4.303903,"median":-0.154011,"eighty":1.038157,"marketCap":3750897925},{"date":"2021-11-12","current":0.929008,"twenty":-4.303903,"median":-0.147568,"eighty":1.038157,"marketCap":3493071374},{"date":"2021-11-19","current":0.866789,"twenty":-4.303903,"median":-0.144043,"eighty":1.038157,"marketCap":3259128044},{"date":"2021-11-26","current":0.862727,"twenty":-4.303903,"median":-0.135656,"eighty":1.038157,"marketCap":3243853393},{"date":"2021-12-03","current":0.867003,"twenty":-4.303903,"median":-0.132933,"eighty":1.038157,"marketCap":3259931973},{"date":"2021-12-10","current":0.957018,"twenty":-4.303903,"median":-0.131401,"eighty":1.038157,"marketCap":3598386069},{"date":"2021-12-17","current":0.907627,"twenty":-4.303903,"median":-0.129637,"eighty":1.038157,"marketCap":3412678477},{"date":"2021-12-23","current":0.890522,"twenty":-4.303903,"median":-0.128172,"eighty":1.038157,"marketCap":3348364160},{"date":"2021-12-31","current":0.913186,"twenty":-4.301729,"median":-0.127623,"eighty":1.037925,"marketCap":3433580630},{"date":"2022-01-07","current":0.923235,"twenty":-4.299556,"median":-0.125931,"eighty":1.037693,"marketCap":3471365292},{"date":"2022-01-14","current":0.94312,"twenty":-4.297382,"median":-0.124796,"eighty":1.037461,"marketCap":3546130686},{"date":"2022-01-21","current":0.8747,"twenty":-4.297382,"median":-0.123683,"eighty":1.037461,"marketCap":3288873416},{"date":"2022-01-28","current":0.908482,"twenty":-4.297382,"median":-0.119566,"eighty":1.037461,"marketCap":3415894193},{"date":"2022-02-04","current":0.943334,"twenty":-4.297382,"median":-0.113467,"eighty":1.037461,"marketCap":3546934615},{"date":"2022-02-11","current":0.923235,"twenty":-4.297382,"median":-0.1075,"eighty":1.037461,"marketCap":3471365292},{"date":"2022-02-18","current":0.867431,"twenty":-4.297382,"median":-0.103418,"eighty":1.037461,"marketCap":3261539831},{"date":"2022-02-25","current":5.165989,"twenty":-4.297382,"median":-0.102228,"eighty":1.041064,"marketCap":3161585251},{"date":"2022-03-04","current":5.545557,"twenty":-4.297382,"median":-0.098825,"eighty":1.052583,"marketCap":3393881054},{"date":"2022-03-11","current":5.426929,"twenty":-4.297382,"median":-0.095621,"eighty":1.068156,"marketCap":3321280393},{"date":"2022-03-18","current":5.554651,"twenty":-4.297382,"median":-0.093491,"eighty":1.082113,"marketCap":3399446559},{"date":"2022-03-25","current":6.319709,"twenty":-4.297382,"median":-0.09226,"eighty":1.086639,"marketCap":3867661893},{"date":"2022-04-01","current":5.824146,"twenty":-4.297382,"median":-0.090741,"eighty":1.099785,"marketCap":3564377169},{"date":"2022-04-08","current":5.839472,"twenty":-4.297382,"median":-0.089288,"eighty":1.109119,"marketCap":3573757109},{"date":"2022-04-14","current":5.72069,"twenty":-4.297382,"median":-0.088072,"eighty":1.112087,"marketCap":3501062575},{"date":"2022-04-22","current":5.49079,"twenty":-4.297382,"median":-0.085936,"eighty":1.122881,"marketCap":3360363476},{"date":"2022-04-29","current":5.135721,"twenty":-4.297382,"median":-0.083434,"eighty":1.128826,"marketCap":3143061534},{"date":"2022-05-06","current":6.317189,"twenty":-4.297382,"median":-0.036731,"eighty":1.133261,"marketCap":3354427300},{"date":"2022-05-13","current":5.948771,"twenty":-4.297382,"median":-0.034058,"eighty":1.135997,"marketCap":3158797658},{"date":"2022-05-20","current":6.138828,"twenty":-4.297382,"median":-0.032649,"eighty":1.139111,"marketCap":3259717711},{"date":"2022-05-27","current":6.608122,"twenty":-4.297382,"median":-0.009371,"eighty":1.144584,"marketCap":3508912612},{"date":"2022-06-03","current":6.673911,"twenty":-4.297382,"median":-0.006676,"eighty":1.15065,"marketCap":3543846476},{"date":"2022-06-10","current":6.877125,"twenty":-4.297382,"median":-0.006101,"eighty":1.15921,"marketCap":3651753302},{"date":"2022-06-17","current":5.682692,"twenty":-4.297382,"median":-0.004946,"eighty":1.174147,"marketCap":3017509584},{"date":"2022-06-24","current":5.565734,"twenty":-4.299556,"median":-0.003394,"eighty":1.179463,"marketCap":2955404936},{"date":"2022-07-01","current":5.815732,"twenty":-4.299556,"median":-0.002473,"eighty":1.20687,"marketCap":3088153621},{"date":"2022-07-08","current":5.768949,"twenty":-4.299556,"median":-0.002422,"eighty":1.217882,"marketCap":3063311762},{"date":"2022-07-15","current":5.995555,"twenty":-4.299556,"median":-0.002351,"eighty":1.236563,"marketCap":3183639518},{"date":"2022-07-22","current":5.82158,"twenty":-4.299556,"median":-0.002233,"eighty":1.260937,"marketCap":3091258854},{"date":"2022-07-29","current":6.558415,"twenty":-4.299556,"median":-0.002174,"eighty":1.32151,"marketCap":3482518136},{"date":"2022-08-05","current":4.050534,"twenty":-4.299556,"median":-0.002096,"eighty":1.342826,"marketCap":3370044551},{"date":"2022-08-12","current":4.168309,"twenty":-4.299556,"median":-0.001964,"eighty":1.378712,"marketCap":3468032874},{"date":"2022-08-19","current":4.409293,"twenty":-4.299556,"median":-0.001896,"eighty":1.401773,"marketCap":3668532058},{"date":"2022-08-26","current":4.541563,"twenty":-4.299556,"median":-0.001796,"eighty":1.45064,"marketCap":3778580482},{"date":"2022-09-02","current":4.189146,"twenty":-4.299556,"median":-0.001178,"eighty":1.545904,"marketCap":3485369269},{"date":"2022-09-09","current":4.14113,"twenty":-4.299556,"median":0.57973,"eighty":1.621675,"marketCap":3445420184},{"date":"2022-09-16","current":3.922794,"twenty":-4.299556,"median":0.621294,"eighty":1.942057,"marketCap":3263764908},{"date":"2022-09-23","current":3.408211,"twenty":-4.299556,"median":0.642916,"eighty":2.736523,"marketCap":2835631313},{"date":"2022-09-30","current":3.481593,"twenty":-4.299556,"median":0.661656,"eighty":2.837464,"marketCap":2896685576},{"date":"2022-10-07","current":3.8476,"twenty":-4.299556,"median":0.671266,"eighty":2.906531,"marketCap":3201203133},{"date":"2022-10-14","current":3.623829,"twenty":-4.299556,"median":0.675351,"eighty":3.023758,"marketCap":3015025320},{"date":"2022-10-21","current":3.988023,"twenty":-4.299556,"median":0.681357,"eighty":3.122843,"marketCap":3318035364},{"date":"2022-10-28","current":3.952691,"twenty":-4.299556,"median":0.687603,"eighty":3.146065,"marketCap":3288638867},{"date":"2022-11-04","current":3.104166,"twenty":-4.299556,"median":0.696733,"eighty":3.174414,"marketCap":3585311802},{"date":"2022-11-11","current":3.033154,"twenty":-4.299556,"median":0.704181,"eighty":3.174414,"marketCap":3503293178},{"date":"2022-11-18","current":2.880016,"twenty":-4.299556,"median":0.715232,"eighty":3.174414,"marketCap":3326417998},{"date":"2022-11-25","current":2.915307,"twenty":-4.299556,"median":0.720758,"eighty":3.174414,"marketCap":3367179356},{"date":"2022-12-02","current":2.813845,"twenty":-4.299556,"median":0.737816,"eighty":3.174414,"marketCap":3249990451},{"date":"2022-12-09","current":2.542228,"twenty":-4.299556,"median":0.780821,"eighty":3.174414,"marketCap":2936273567},{"date":"2022-12-16","current":2.720575,"twenty":-4.299556,"median":0.785146,"eighty":3.174414,"marketCap":3142264003},{"date":"2022-12-23","current":2.741372,"twenty":-4.299556,"median":0.78875,"eighty":3.174414,"marketCap":3166284090},{"date":"2022-12-30","current":2.742002,"twenty":-4.299556,"median":0.793555,"eighty":3.174414,"marketCap":3167011971},{"date":"2023-01-06","current":2.651883,"twenty":-4.274667,"median":0.799561,"eighty":3.174414,"marketCap":3062924931},{"date":"2023-01-13","current":2.876234,"twenty":-4.219877,"median":0.829273,"eighty":3.174414,"marketCap":3322050709},{"date":"2023-01-20","current":2.982108,"twenty":-4.167301,"median":0.834376,"eighty":3.174414,"marketCap":3444334784},{"date":"2023-01-27","current":2.719945,"twenty":-4.084814,"median":0.845858,"eighty":3.174414,"marketCap":3141536122},{"date":"2023-02-03","current":2.569327,"twenty":-4.03426,"median":0.854679,"eighty":3.174414,"marketCap":2967572467},{"date":"2023-02-10","current":2.677721,"twenty":-4.008224,"median":0.863582,"eighty":3.174414,"marketCap":3092768068},{"date":"2023-02-17","current":2.493703,"twenty":-3.990086,"median":0.867003,"eighty":3.174414,"marketCap":2880226699},{"date":"2023-02-24","current":5.825747,"twenty":-3.906528,"median":0.87299,"eighty":3.191675,"marketCap":3052691405},{"date":"2023-03-03","current":5.999019,"twenty":-3.906528,"median":0.880046,"eighty":3.256836,"marketCap":3143485739},{"date":"2023-03-10","current":5.507855,"twenty":-3.906528,"median":0.883253,"eighty":3.347056,"marketCap":2886115972},{"date":"2023-03-17","current":4.791999,"twenty":-3.906528,"median":0.885824,"eighty":3.415786,"marketCap":2511007373},{"date":"2023-03-24","current":5.025358,"twenty":-3.906528,"median":0.893516,"eighty":3.480099,"marketCap":2633287460},{"date":"2023-03-31","current":5.223442,"twenty":-3.906126,"median":0.900969,"eighty":3.517215,"marketCap":2737083349},{"date":"2023-04-06","current":5.398461,"twenty":-3.906126,"median":0.906986,"eighty":3.537959,"marketCap":2828793414},{"date":"2023-04-14","current":5.525994,"twenty":-3.874187,"median":0.910407,"eighty":3.580043,"marketCap":2895620904},{"date":"2023-04-21","current":5.345548,"twenty":-3.063777,"median":0.913186,"eighty":3.644587,"marketCap":2801067115},{"date":"2023-04-28","current":5.331981,"twenty":-2.9157,"median":0.91789,"eighty":3.660877,"marketCap":2793957808},{"date":"2023-05-05","current":2.710499,"twenty":-2.83461,"median":0.923235,"eighty":3.676244,"marketCap":2710498650},{"date":"2023-05-12","current":2.780342,"twenty":-2.714739,"median":0.924416,"eighty":3.676244,"marketCap":2780342316},{"date":"2023-05-19","current":2.80574,"twenty":-2.651277,"median":0.929008,"eighty":3.676244,"marketCap":2805740013},{"date":"2023-05-26","current":2.804329,"twenty":-2.545508,"median":0.93136,"eighty":3.676244,"marketCap":2804329030},{"date":"2023-06-02","current":2.675224,"twenty":-2.467945,"median":0.93644,"eighty":3.676244,"marketCap":2675224071},{"date":"2023-06-09","current":2.91368,"twenty":-2.316342,"median":0.942265,"eighty":3.676244,"marketCap":2913680225},{"date":"2023-06-16","current":3.019504,"twenty":-2.192945,"median":0.944095,"eighty":3.676244,"marketCap":3019503962},{"date":"2023-06-23","current":3.033614,"twenty":-1.718042,"median":0.948848,"eighty":3.679803,"marketCap":3033613794},{"date":"2023-06-30","current":3.224802,"twenty":-1.017941,"median":0.957018,"eighty":3.683362,"marketCap":3224802012},{"date":"2023-07-07","current":3.126739,"twenty":-1.0117,"median":0.960652,"eighty":3.683362,"marketCap":3126738682},{"date":"2023-07-14","current":3.32216,"twenty":-1.004921,"median":0.967067,"eighty":3.683362,"marketCap":3322159850},{"date":"2023-07-21","current":3.467491,"twenty":-0.982348,"median":0.971585,"eighty":3.683362,"marketCap":3467491115},{"date":"2023-07-28","current":3.629754,"twenty":-0.970637,"median":0.996403,"eighty":3.683362,"marketCap":3629754179},{"date":"2023-08-04","current":3.965138,"twenty":-0.961085,"median":1.005213,"eighty":3.710729,"marketCap":3596379773},{"date":"2023-08-11","current":4.167386,"twenty":-0.952225,"median":1.01715,"eighty":3.727573,"marketCap":3779819278},{"date":"2023-08-18","current":4.15294,"twenty":-0.92449,"median":1.033875,"eighty":3.745954,"marketCap":3766716456},{"date":"2023-08-25","current":4.147618,"twenty":-0.908697,"median":1.038389,"eighty":3.807376,"marketCap":3761889101},{"date":"2023-09-01","current":4.245701,"twenty":-0.892518,"median":1.046068,"eighty":3.835822,"marketCap":3850850364},{"date":"2023-09-08","current":4.253304,"twenty":-0.869791,"median":1.057139,"eighty":3.859377,"marketCap":3857746586},{"date":"2023-09-15","current":4.409932,"twenty":-0.842442,"median":1.07614,"eighty":3.897468,"marketCap":3999808760},{"date":"2023-09-22","current":4.213006,"twenty":-0.808929,"median":1.083204,"eighty":3.922794,"marketCap":3821196610},{"date":"2023-09-29","current":4.397007,"twenty":-0.773875,"median":1.091536,"eighty":3.973528,"marketCap":3988085182},{"date":"2023-10-06","current":3.991749,"twenty":-0.70608,"median":1.106481,"eighty":3.985769,"marketCap":3620516550},{"date":"2023-10-13","current":4.141535,"twenty":-0.590904,"median":1.111225,"eighty":4.007048,"marketCap":3756372123},{"date":"2023-10-20","current":4.1978,"twenty":-0.536975,"median":1.119798,"eighty":4.025939,"marketCap":3807404166},{"date":"2023-10-27","current":4.029006,"twenty":-0.518093,"median":1.126535,"eighty":4.028558,"marketCap":3654308037},{"date":"2023-11-03","current":7.887836,"twenty":-0.278454,"median":1.132317,"eighty":4.047258,"marketCap":3620516550},{"date":"2023-11-10","current":7.576588,"twenty":-0.034677,"median":1.134676,"eighty":4.075326,"marketCap":3477654048},{"date":"2023-11-17","current":7.666287,"twenty":-0.0331,"median":1.137946,"eighty":4.100348,"marketCap":3518825959},{"date":"2023-11-24","current":7.735057,"twenty":-0.031186,"median":1.139866,"eighty":4.114893,"marketCap":3550391090},{"date":"2023-12-01","current":7.655823,"twenty":-0.007262,"median":1.146471,"eighty":4.140768,"marketCap":3514022569},{"date":"2023-12-08","current":7.343371,"twenty":-0.006175,"median":1.153272,"eighty":4.15294,"marketCap":3370607081},{"date":"2023-12-15","current":7.699177,"twenty":-0.005661,"median":1.164163,"eighty":4.166853,"marketCap":3533922326},{"date":"2023-12-21","current":8.083389,"twenty":-0.004329,"median":1.174914,"eighty":4.173165,"marketCap":3710275343},{"date":"2023-12-29","current":8.213452,"twenty":-0.002728,"median":1.179572,"eighty":4.184722,"marketCap":3769974613},{"date":"2024-01-05","current":7.787381,"twenty":-0.002424,"median":1.200531,"eighty":4.190957,"marketCap":3574408038},{"date":"2024-01-12","current":7.663298,"twenty":-0.002376,"median":1.215841,"eighty":4.213006,"marketCap":3517453562},{"date":"2024-01-19","current":7.540709,"twenty":-0.002348,"median":1.23323,"eighty":4.21852,"marketCap":3461185284},{"date":"2024-01-26","current":7.703662,"twenty":-0.00223,"median":1.25325,"eighty":4.229765,"marketCap":3535980922},{"date":"2024-02-02","current":7.107163,"twenty":-0.00217,"median":1.308157,"eighty":4.245701,"marketCap":3262187716},{"date":"2024-02-09","current":8.022094,"twenty":-0.002082,"median":1.341101,"eighty":4.269271,"marketCap":3682141204},{"date":"2024-02-16","current":8.139367,"twenty":-0.001939,"median":1.357573,"eighty":4.305767,"marketCap":3735969362},{"date":"2024-02-23","current":8.27369,"twenty":-0.001896,"median":1.390517,"eighty":4.333899,"marketCap":3797623594},{"date":"2024-03-01","current":6.407884,"twenty":-0.001842,"median":1.402185,"eighty":4.370203,"marketCap":3614046387},{"date":"2024-03-08","current":6.000098,"twenty":-0.001842,"median":1.402185,"eighty":4.398139,"marketCap":3384055319},{"date":"2024-03-15","current":6.635114,"twenty":-0.001842,"median":1.402185,"eighty":4.486299,"marketCap":3742204060},{"date":"2024-03-22","current":6.837155,"twenty":-0.001842,"median":1.402185,"eighty":4.590123,"marketCap":3856155238},{"date":"2024-03-28","current":6.696949,"twenty":-0.001842,"median":1.402185,"eighty":4.889684,"marketCap":3777079302},{"date":"2024-04-05","current":6.605511,"twenty":-0.001842,"median":1.400126,"eighty":5.026714,"marketCap":3725508039},{"date":"2024-04-12","current":6.893237,"twenty":-0.001842,"median":1.400126,"eighty":5.165989,"marketCap":3887785613},{"date":"2024-04-19","current":6.545771,"twenty":-0.001842,"median":1.400126,"eighty":5.223442,"marketCap":3691814813},{"date":"2024-04-26","current":6.737182,"twenty":-0.001842,"median":1.402185,"eighty":5.288565,"marketCap":3799770657},{"date":"2024-05-03","current":6.278771,"twenty":-0.001842,"median":1.402185,"eighty":5.337699,"marketCap":3541226726},{"date":"2024-05-10","current":13.595091,"twenty":-0.001842,"median":1.402185,"eighty":5.365367,"marketCap":3439558041},{"date":"2024-05-17","current":13.340471,"twenty":-0.001842,"median":1.402185,"eighty":5.398279,"marketCap":3375139142},{"date":"2024-05-24","current":12.657872,"twenty":-0.001842,"median":1.402185,"eighty":5.428033,"marketCap":3202441667},{"date":"2024-05-31","current":12.76893,"twenty":-0.001842,"median":1.402185,"eighty":5.474551,"marketCap":3230539272},{"date":"2024-06-07","current":12.771639,"twenty":-0.001842,"median":1.402185,"eighty":5.522366,"marketCap":3231224579},{"date":"2024-06-14","current":13.283588,"twenty":-0.001842,"median":1.400126,"eighty":5.545711,"marketCap":3360747685},{"date":"2024-06-21","current":13.440694,"twenty":-0.00185,"median":1.396694,"eighty":5.56864,"marketCap":3400495517},{"date":"2024-06-28","current":14.203543,"twenty":-0.001873,"median":1.390517,"eighty":5.588625,"marketCap":3593496288},{"date":"2024-07-05","current":18.737699,"twenty":-0.001873,"median":1.390517,"eighty":5.623622,"marketCap":4740637844},{"date":"2024-07-12","current":18.734158,"twenty":-0.001873,"median":1.390517,"eighty":5.681579,"marketCap":4739742032},{"date":"2024-07-15","current":18.199504,"twenty":-0.001873,"median":1.390517,"eighty":5.682628,"marketCap":4604474399},{"date":"2024-08-02","current":17.324936,"twenty":-0.001911,"median":1.346824,"eighty":5.705155,"marketCap":4383208801},{"date":"2024-08-09","current":26.336533,"twenty":-0.001911,"median":1.353001,"eighty":5.730738,"marketCap":4319191489},{"date":"2024-08-16","current":27.446127,"twenty":-0.001911,"median":1.366496,"eighty":5.752282,"marketCap":4501164861},{"date":"2024-08-23","current":27.935654,"twenty":-0.001911,"median":1.402185,"eighty":5.768949,"marketCap":4581447230},{"date":"2024-08-30","current":28.947342,"twenty":-0.001911,"median":1.534648,"eighty":5.815918,"marketCap":4747364128},{"date":"2024-09-06","current":26.798864,"twenty":-0.001911,"median":1.621812,"eighty":5.830215,"marketCap":4395013727},{"date":"2024-09-13","current":26.532344,"twenty":-0.001911,"median":2.339797,"eighty":5.906847,"marketCap":4351304437},{"date":"2024-09-20","current":28.69714,"twenty":-0.001911,"median":2.536241,"eighty":5.949941,"marketCap":4706330917},{"date":"2024-09-27","current":27.065384,"twenty":-0.001911,"median":2.572163,"eighty":5.993801,"marketCap":4438723018},{"date":"2024-10-04","current":29.175788,"twenty":-0.001911,"median":2.598946,"eighty":6.004674,"marketCap":4784829234},{"date":"2024-10-11","current":28.196735,"twenty":-0.001911,"median":2.632346,"eighty":6.084735,"marketCap":4624264494},{"date":"2024-10-18","current":28.457816,"twenty":-0.001911,"median":2.652829,"eighty":6.188884,"marketCap":4667081758},{"date":"2024-10-25","current":28.909268,"twenty":-0.001911,"median":2.676473,"eighty":6.29292,"marketCap":4741119943},{"date":"2024-10-31","current":28.457816,"twenty":-0.001911,"median":2.700529,"eighty":6.318197,"marketCap":4667081758},{"date":"2024-11-08","current":9.769816,"twenty":-0.001911,"median":2.720575,"eighty":6.403954,"marketCap":5187772215},{"date":"2024-11-15","current":10.08759,"twenty":-0.001911,"median":2.730028,"eighty":6.445337,"marketCap":5356510077},{"date":"2024-11-22","current":10.289652,"twenty":-0.001911,"median":2.745773,"eighty":6.495297,"marketCap":5463805348},{"date":"2024-11-29","current":10.217117,"twenty":-0.001911,"median":2.769054,"eighty":6.509101,"marketCap":5425289097},{"date":"2024-12-06","current":9.553937,"twenty":-0.001911,"median":2.793041,"eighty":6.54466,"marketCap":5073140515},{"date":"2024-12-13","current":9.540121,"twenty":-0.001911,"median":2.802213,"eighty":6.559607,"marketCap":5065804086},{"date":"2024-12-20","current":8.804405,"twenty":-0.001911,"median":2.809973,"eighty":6.611052,"marketCap":4675139252},{"date":"2024-12-27","current":8.8424,"twenty":-0.001911,"median":2.83149,"eighty":6.63564,"marketCap":4695314432},{"date":"2025-01-03","current":8.98229,"twenty":-0.001911,"median":2.859849,"eighty":6.695486,"marketCap":4769595773},{"date":"2025-01-10","current":9.056419,"twenty":-0.001912,"median":2.878125,"eighty":6.715023,"marketCap":4808958516},{"date":"2025-01-17","current":9.287002,"twenty":-0.001912,"median":2.910877,"eighty":6.768152,"marketCap":4931398273},{"date":"2025-01-24","current":9.164828,"twenty":-0.001912,"median":2.92539,"eighty":6.812937,"marketCap":4866523476},{"date":"2025-01-31","current":8.779375,"twenty":-0.001912,"median":2.958773,"eighty":6.905886,"marketCap":4661848062},{"date":"2025-02-07","current":8.251098,"twenty":-0.001912,"median":2.977067,"eighty":7.022037,"marketCap":4381333096},{"date":"2025-02-14","current":7.96545,"twenty":-0.001912,"median":3.016876,"eighty":7.290747,"marketCap":4229653994},{"date":"2025-02-21","current":8.393922,"twenty":-0.001912,"median":3.041727,"eighty":7.484796,"marketCap":4457172647},{"date":"2025-02-28","current":7.688406,"twenty":-0.001893,"median":3.115452,"eighty":7.51948,"marketCap":4082543540},{"date":"2025-03-07","current":9.891447,"twenty":-0.001794,"median":3.192349,"eighty":7.555659,"marketCap":3719184042},{"date":"2025-03-14","current":10.152193,"twenty":-0.001042,"median":3.260077,"eighty":7.584063,"marketCap":3817224529},{"date":"2025-03-21","current":10.724385,"twenty":0.607359,"median":3.33664,"eighty":7.655823,"marketCap":4032368932},{"date":"2025-03-28","current":10.680928,"twenty":0.634508,"median":3.474546,"eighty":7.696187,"marketCap":4016028850},{"date":"2025-04-04","current":9.797289,"twenty":0.645015,"median":3.602945,"eighty":7.709642,"marketCap":3683780532},{"date":"2025-04-11","current":8.073821,"twenty":0.663604,"median":3.657801,"eighty":7.734459,"marketCap":3035756810},{"date":"2025-04-15","current":8.290795,"twenty":0.667358,"median":3.694493,"eighty":7.739841,"marketCap":3117338809}],"updateTime":1744845957073}}}